Savvy Trades and Investments

[Trent Blair]

MPH.V MCUJF Remember there are 2 drugs in the pipeline and a acquisition too. Now I believe the 2023 patent covers well over 70% of their sales if not more. When a competitor had supply issues the majority of the hospitals that used the product kept ordering. Generics are somewhat competitive but not competitive on quality or price. I think the generics would like to gain 10% of the market at 80% gross margins than half the market at 30% gross margins but I could be wrong on that.